Next report date
Report period
Q1 2024
EPS estimate
−0.14EUR
Revenue estimate
5.47 MEUR
−0.64EUR
−54.68 MEUR
14.92 MEUR
57.28 M
About AC Immune SA
Sector
CEO
Andrea Pfeifer
Headquarters
Lausanne
Website
Employees (FY)
161
Founded
2003
ISIN
CH0329023102
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IMR is 2.28 EUR — it hasn't changed in the past 24 hours. Watch AC IMMUNE LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange AC IMMUNE LTD stocks are traded under the ticker IMR.
AC IMMUNE LTD is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
IMR stock is 2.44% volatile and has beta coefficient of 1.45. Track AC IMMUNE LTD stock price on the chart and check out the list of the most volatile stocks — is AC IMMUNE LTD there?
IMR earnings for the last quarter are −0.19 EUR per share, whereas the estimation was 0.03 EUR resulting in a −695.32% surprise. The estimated earnings for the next quarter are −0.10 EUR per share. See more details about AC IMMUNE LTD earnings.
Yes, you can track AC IMMUNE LTD financials in yearly and quarterly reports right on TradingView.
IMR stock has risen by 3.17% compared to the previous week, the month change is a 12.84% fall, over the last year AC IMMUNE LTD has showed a 35.74% increase.
IMR net income for the last quarter is −4.84 M EUR, while the quarter before that showed −16.21 M EUR of net income which accounts for 70.12% change. Track more AC IMMUNE LTD financial stats to get the full picture.
Today AC IMMUNE LTD has the market capitalization of 231.45 M, it has decreased by 1.53% over the last week.
No, IMR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AC IMMUNE LTD stock right from TradingView charts — choose your broker and connect to your account.
As of May 2, 2024, the company has 161.00 employees. See our rating of the largest employees — is AC IMMUNE LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AC IMMUNE LTD technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AC IMMUNE LTD stock shows the strong sell signal. See more of AC IMMUNE LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on AC IMMUNE LTD future price: according to them, IMR price has a max estimate of 14.58 EUR and a min estimate of 6.13 EUR. Watch IMR chart and read a more detailed AC IMMUNE LTD stock forecast: see what analysts think of AC IMMUNE LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AC IMMUNE LTD EBITDA is −53.13 M EUR, and current EBITDA margin is −357.37%. See more stats in AC IMMUNE LTD financial statements.